ViatrisHAM:VIA +1.71%58 Dividend Yield % is 2.89% as of Jun. 26, 2026, which is 32% below its 10-year median of 4.22. GuruFocus rates HAM:VIA with a GF Score™ of 58/100 and a GF Value™ of €9.77 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 516 Drug Manufacturers companies, Viatris ranks better than 64.34% on this metric.
As of today (2026-06-26), the Trailing Annual Dividend Yield of Viatris is 2.89%.
Warning Sign:
Viatris Inc stock Dividend Yield % is close to 3-year low.
The historical rank and industry rank for Viatris's Dividend Yield % or its related term are showing as below:
HAM:VIA'
s Dividend Yield % Range Over the Past 10 Years
Min: 0.74 Med: 4.22 Max: 6.37
Current: 2.89
During the past 13 years, the highest Dividend Yield of Viatris was 6.37%. The lowest was 0.74%. And the median was 4.22%.
HAM:VIA's Dividend Yield % is ranked better than 64.34% of 516
companies
in the Drug Manufacturers industry
Industry Median: 2.03
vs HAM:VIA: 2.89
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Viatris was 62.40% per year. The lowest was 0.00% per year. And the median was 14.05% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Viatris (HAM:VIA) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for Viatris's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:VIA vs NBIX, UTHR, ELAN: Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Viatris's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Viatris Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
USD 0.120000
2026-05-22
2026-05-22
2026-06-17
Cash Dividend
quarterly
USD:EUR 0.856000
USD 0.120000
2026-03-09
2026-03-09
2026-03-18
Cash Dividend
quarterly
USD:EUR 0.865000
USD 0.120000
2025-11-24
2025-11-24
2025-12-15
Cash Dividend
quarterly
USD:EUR 0.865000
USD 0.120000
2025-08-22
2025-08-22
2025-09-15
Cash Dividend
quarterly
USD:EUR 0.859000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Viatris's Trailing Annual Dividend Yield (%) for Today is calculated as
Trailing Annual Dividend Yield
=
Most Recent Full Year Dividend
/
Current Share Price
=
0.4134
/
14.256
=
2.90 %
Current Share Price is €14.256. Viatris's Dividends per Share for the trailing twelve months (TTM) ended in Today is €0.4134.
Viatris's Forward Annual Dividend Yield (%) for Today is calculated as
Forward Annual Dividend Yield
=
Forward Full Year Dividend
/
Current Share Price
=
0.41088
/
14.256
=
2.88 %
Current Share Price is €14.256. Viatris's Dividends per Share for the forward twelve months is calculated as €0.10272 * 4 = €0.41088.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris (HAM:VIA) has a Dividend Yield % of 2.89% as of Jun. 26, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Viatris and its competitors. This is 32% below median its historical median of 4.22. Over the past decade, Viatris' Dividend Yield % has ranged from 0.74 to 6.37. According to the industry distribution chart, Viatris ranks #184 out of 516 companies in the Drug Manufacturers industry, placing it in the top 35.7%.
Is Viatris' Dividend Yield % too high?
Viatris' current Dividend Yield % of 2.89% is 32% below median its 10-year median of 4.22. Over the past 10 years, this metric has ranged from a low of 0.74 to a high of 6.37. The Drug Manufacturers industry median Dividend Yield % is 2.03. Viatris' value of 2.89% is 42.4% above this industry median. Based on the distribution chart, Viatris ranks #184 out of 516 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Viatris has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' Dividend Yield % compare to NBIX and UTHR?
According to the Drug Manufacturers industry distribution chart, Viatris ranks #184 out of 516 companies for Dividend Yield %. This puts Viatris in the upper half of its industry. The industry median Dividend Yield % is 2.03. Viatris' value of 2.89% is 42.4% above this benchmark. Historically, Viatris' own Dividend Yield % has ranged from 0.74 to 6.37 over the past decade. While the company's 10-year median is 4.22 vs. the industry median of 2.03, Viatris has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 2.03, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viatris's current Dividend Yield % of 2.89% is 42.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Viatris and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viatris's current Dividend Yield % is 2.89%, which is 32% below median its own 10-year median of 4.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (HAM:VIA) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.77, compared to a current price of €14.26 — trading 45.9% above its estimated fair value. The current Dividend Yield % is 2.89%, which is 32% below median its 10-year median of 4.22 and 42.4% above the Drug Manufacturers industry median of 2.03. Viatris' overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Viatris (HAM:VIA), the current Dividend Yield % is 2.89% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viatris (HAM:VIA) Overvalued in 2026?
Based on GuruFocus' analysis, Viatris stock appears to be overvalued.
The current stock price of €14.26 is trading 45.9% above its estimated GF Value™ of €9.77.
GuruFocus considers Viatris to be Significantly Overvalued.
Key valuation signals for HAM:VIA:
Dividend Yield %: 2.89% (32% below median its 10-year median of 4.22)
GF Value™: €9.77 vs. price of €14.26 (45.9% above fair value)
Industry Position: 42.4% above the Drug Manufacturers median (#184 of 516)
No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
58GF Score
Get the complete analysis for HAM:VIA
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:VIA has been successfully added to your 
